SALT LAKE CITY, Jan. 2, 2013 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a company dedicated to helping people achieve healthy living through a combination of a compelling business opportunity and scientifically validated products, including its patented dietary supplement Protandim ®, the Nrf2 Synergizer ®, announced today that a new peer-reviewed study involving Protandim was published in the November 2012 issue of the scientific journal, Free Radical Biology and Medicine. Protandim, comprised of five highly synergistic herbal ingredients, has been shown in earlier studies to activate the transcription factor Nrf2, a signal to the cell's DNA to regulate a network of protective genes. The new study titled, "Upregulation of phase II enzymes through phytochemical activation of Nrf2 protects cardiomyocytes against oxidant stress," further investigates Protandim's ability to induce protective responses in cultured mouse heart muscle cells. "This newest research, one among numerous published peer-reviewed studies involving Protandim, provides further evidence of the scientific integrity of our healthy living products," said LifeVantage President and CEO Douglas C. Robinson. "As we expand our international operations and broaden our product range, we will continue to encourage and support rigorous scientific examination of the function and benefits of our offerings." According to Darlene Walley, Ph.D., LifeVantage Chief Science Officer, "This study, conceived and conducted by researchers at two Colorado universities, shows the remarkable academic interest of the scientific community in Protandim and demonstrates Protandim's powerful ability to activate Nrf2, an important pathway for reducing and protecting cells against oxidative stress. We are honored to be involved in cutting edge research regarding Nrf2, Protandim's robust impact on its activation, and the important positive ways that Nrf2 activation can potentially impact health and reduce oxidative stress." The key findings of this latest research are:
1) Protandim treatment of cultured HL-1 cells (mouse cardiomyocytes) caused Nrf2 activation, as measured by nuclear accumulation of Nrf2 and by increased expression of phase II enzymes heme oxygenase-1, superoxide dismutase-1, and glutathione reductase.